BidaskClub cut shares of TESARO, Inc. (NASDAQ:TSRO) from a sell rating to a strong sell rating in a research note released on Wednesday morning.
Several other research analysts also recently issued reports on TSRO. Zacks Investment Research downgraded shares of TESARO from a hold rating to a sell rating in a report on Wednesday, March 22nd. Argus initiated coverage on shares of TESARO in a research report on Friday, March 24th. They issued a buy rating and a $210.00 price target on the stock. Jefferies Group LLC boosted their price target on shares of TESARO from $80.00 to $124.00 and gave the company a hold rating in a research report on Monday, March 27th. Vetr upgraded shares of TESARO from a buy rating to a strong-buy rating and set a $178.33 price target on the stock in a research report on Monday, March 27th. Finally, Cowen and Company reiterated a market perform rating and set a $145.00 target price on shares of TESARO in a research report on Tuesday, March 28th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $173.74.
Shares of TESARO (NASDAQ TSRO) traded up 4.43% during midday trading on Wednesday, hitting $129.51. The stock had a trading volume of 749,038 shares. The firm has a 50 day moving average of $139.60 and a 200-day moving average of $151.77. The company’s market cap is $6.98 billion. TESARO has a one year low of $83.26 and a one year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. TESARO’s revenue was up 909.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.22) EPS. On average, analysts forecast that TESARO will post ($8.66) earnings per share for the current fiscal year.
In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 40.50% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of the company. Macquarie Group Ltd. increased its stake in TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock valued at $40,547,000 after buying an additional 13,830 shares in the last quarter. Shell Asset Management Co. increased its position in shares of TESARO by 32.5% in the first quarter. Shell Asset Management Co. now owns 7,807 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 1,913 shares during the period. Bellevue Group AG purchased a new position in shares of TESARO during the first quarter worth about $2,462,000. First Citizens Bank & Trust Co. purchased a new position in shares of TESARO during the first quarter worth about $288,000. Finally, First Trust Advisors LP purchased a new position in shares of TESARO during the first quarter worth about $3,993,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with our FREE daily email newsletter.